Animal-derived materials: still here, increasingly documented
Collagen, gelatin, heparin and porcine and bovine tissue remain in wide device use. What sourcing control actually involves, and where recombinant alternatives have arrived.
It is easy to assume that synthetic materials displaced animal-derived ones in medical devices. In wound closure they largely did — surgical gut is a much smaller category than it was. Across devices as a whole, animal-derived materials remain widespread, and the framework governing them has become considerably more demanding.
Where they still are
Collagen, mostly bovine or porcine, appears in haemostats, wound dressings, tissue scaffolds and barrier layers. Gelatin, a collagen derivative, is used in haemostatic sponges and as a carrier in combination products. Heparin, conventionally derived from porcine intestinal mucosa, is used to coat blood-contacting surfaces. Bovine and porcine pericardium is used in heart valves and surgical patches. Chitosan, from crustacean shells, appears in haemostatic dressings. And surgical gut, from bovine or ovine intestinal serosa, remains in use in some settings.
These are not legacy materials awaiting replacement. In several applications the animal-derived material performs a function — a collagen scaffold that cells populate and remodel — that no synthetic reproduces.
The risk that shaped the framework
The controls in this area were built in response to transmissible spongiform encephalopathies. The BSE episode established that a pathogen could be present in animal tissue, resist conventional inactivation, and transmit through a biological route — and it reset expectations for any device incorporating animal material permanently.
The resulting framework works on several layers at once, which is the appropriate response to a hazard that cannot be tested away.
Species and geographical sourcing. Material must come from species and from countries or regions with an assessed risk status, from animals fit for human consumption, and from source countries with functioning veterinary surveillance.
Tissue selection. Different tissues carry different infectivity risk. Sourcing from lower-risk tissues is a primary control rather than a refinement.
Traceability. Documented traceability from the finished device back to the source herd or flock, maintained as records rather than assertions.
Processing. Manufacturing steps with demonstrated capacity to inactivate or remove the agent, validated for that purpose specifically.
In the European framework, devices manufactured using animal tissue that is rendered non-viable are subject to specific additional requirements and to scrutiny by a notified body, and that assessment is separate from the general conformity assessment. Similar structures exist in other jurisdictions.
Immunological considerations
A second consideration sits alongside infectivity: an animal-derived material is recognised by the immune system as foreign. Processing to reduce immunogenicity — decellularisation, crosslinking, removal of specific antigenic components — is a standard part of manufacture, and the extent of it is a design decision with consequences for how the material behaves in the body.
This is also where the historical case for synthetics was strongest in wound closure. Enzymatic degradation of a collagen-derived suture varies between patients in a way that hydrolysis of a synthetic polymer does not, and the tissue response differs. That predictability argument, rather than any single failure, is what moved the category.
Where alternatives have actually arrived
Recombinant production — expressing a protein in a bacterial, yeast or plant system rather than extracting it from an animal — removes the sourcing risk at the origin. It is established for some proteins and not for others, and the constraint is usually the difficulty of producing a structurally correct complex protein at scale and at cost.
Recombinant human collagen and gelatin exist and are advancing. Recombinant thrombin is available. Synthetic scaffold materials substitute for collagen in some applications and not in others. The pattern is that simpler molecules have been substituted and structurally complex tissues, such as a pericardial patch, have not.
Non-technical drivers
Two pressures are growing that have nothing to do with safety. Patient acceptability is a real consideration — religious observance, dietary practice and personal preference all bear on whether a patient consents to a porcine- or bovine-derived implant, and disclosure of animal origin is an ethical expectation independent of any regulatory requirement. Supply resilience is the second: material tied to a specific species from specific regions is exposed to animal disease outbreaks and to export restrictions in a way a synthetic is not.
Neither will remove animal-derived materials from devices in the near term. Both are steadily raising the value of knowing exactly where a material came from — which, as with chemical restriction, is turning documentation into a strategic asset rather than a compliance cost.
Dolphin Sutures’ surgical gut sutures are described on their product page; sourcing and processing controls for any device are covered in its technical documentation.
This article summarises developments reported publicly across the medical-device trade press, conference programmes and clinical literature. It is general professional information — not clinical guidance, and not a claim about any Dolphin Sutures product. Device selection, indications and technique rest with the treating surgeon; refer to the Instructions for Use supplied with any device.
Talk to our team
Bulk pricing, OEM manufacturing and export documentation — response within one business day.